[1] RYBICKA A,KROL M.Identification and characterization of cancer stem cells in canine mammary tumors[J].Acta Veterinaria Scandinavica,2016,58(1):86. [2] SHAFIEE R,JAVANBAKHT J,ATYBI N,et al.Retracted article:Diagnosis,classification and grading of canine mammary tumours as a model to study human breast cancer:An clinico-cytohistopathological study with environmental factors influencing public health and medicine[J].Cancer Cell International,2013,13(1):469. [3] 师金,梁迪,李道娟,等.全球女性乳腺癌流行情况研究[J].中国肿瘤,2017,26(9):683-690. SHI J,LIANG D,LI D J,et al.Epidemiological status of global female breast cancer[J].China Cancer,2017,26(9):683-690.(in Chinese) [4] 郭鱼波,王春晖,裴晓华.乳腺癌细胞上皮间质转化的分子机制及其防治的研究进展[J].中国肿瘤,2018,27(12):933-943. GUO Y B,WANG C H,PEI X Y.Research progress on molecular mechanism of epithelial mesenchymal transition in breast cancer cells and its prevention and treatment[J].China Cancer,2018,27(12):933-943.(in Chinese) [5] ACLOQUE H,ADAMS M S,FISHWICK K,et al.Epithelial-mesenchymal transitions:The importance of changing cell state in development and disease[J].Journal of Clinicla Investigation,2009,119(6):1438-1449. [6] GREENBURG G.Epithelia suspended in collagen gels can lose polarity and express characteristics of migrating mesenchymal cells[J].Journal of Cell Biology,1982,95(1):333-339. [7] 庞翠,张菊,刘文超.EMT研究进展[J].现代肿瘤医学,2016,24(15):2484-2487. PANG C,ZHANG J,LIU W C.The research progression of EMT[J].Modern Oncology,2016,24(15):2484-2487.(in Chinese) [8] ZEISBERG M,NEILSON E G.Biomarkers for epithelial-mesenchymal transitions[J].Journal of Clinicl Investigation,2009,119(6):1429-1437. [9] LAMOUILLE S,XU J,DERYNCK R.Molecular mechanisms of epithelial-mesenchymal transition[J].Nature Reviews Molecular Cell Biology,2014,15(3):178-196. [10] FUXE J,KARLSSON M C.TGF-β-induced epithelial-mesenchymal transition:A link between cancer and inflammation[J].Seminars in Cancer Biology,2012,22(5-6):455-461. [11] 周珏,李海莉,贾秀鹏,等.乳腺癌上皮间质转化的研究进展[J].现代实用医学,2019,31(12):1697-1699. ZHOU Y,LI H L,JIA X P,et al.The research progress of breast cancer epithelial-mesenchymal transition[J].Modern Practical Medicine,2019,31(12):1697-1699.(in Chinese) [12] MOSES H L,ROBERTS A B,DERYNCK R.The discovery and early days of TGF-β:A historical perspective[J].Cold Spring Harbor Perspectives in Biology,2016,8(7):a021865. [13] HAQUE S,MORRIS J C.Transforming growth factor-β:A therapeutic target for cancer[J].Human Vaccines Immunotherapeutics,2017,13(8):1741-1750. [14] DERYNCK R,BUDI E H.Specificity,versatility,and control of TGF-β family signaling[J].Science Signaling,2019,12(570):eaav5183. [15] HELDIN C H,MOUSTAKAS A.Signaling receptors for TGF-β family members[J].Cold Spring Harbor Perspectives in Biology,2016,8(8):a022053. [16] HAO Y,BAKER D,TEN DIJKE P.TGF-β-mediated epithelial-mesenchymal transition and cancer metastasis[J].International Journal of Molecular Sciences,2019,20(11):2767. [17] YAN X,LIAO H,CHENG M,et al.Smad7 protein interacts with receptor-regulated Smads (R-Smads) to inhibit transforming growth factor-β (TGF-β)/Smad signaling[J].The Journal of Bioligical Chemistry,2016,291(1):382-392. [18] HATA A,CHEN Y G.TGF-β signaling from receptors to Smads[J].Cold Spring Harbor Perspectives Biology,2016,8(9):a022061. [19] HUBER M A,AZOITEI N,BAUMANN B,et al.NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression[J].The Journal of Clinical Investigation,2004,114(4):569-581. [20] PIRES B R,MENCALLHA A L,FERREIRA G M,et al.NF-κB is involved in the regulation of EMT genes in breast cancer cells[J].PLoS One,2017,12(1):e0169622. [21] JAMSHIDI M,FAGERHOLM R,KHAN S,et al.SNP-SNP interaction analysis of NF-κB signaling pathway on breast cancer survival[J].Oncotarget,2015,6(35):37979-37994. [22] ZHAN T,RINDTORFF N,BOUTROS M.Wnt signa-ling in cancer[J].Oncogene,2017,36(11):1461-1473. [23] NAYAK L,BHATTCHARYYA N P,DE R K.Wnt signal transduction pathways:Modules,development and evolution[J].BMC Systems Biology,2016,10(Suppl 2):44. [24] KRISHNAMURTHY N,KURZROCK R.Targeting the Wnt/β-catenin pathway in cancer:Update on effectors and inhibitors[J].Cancer Treatment Reviews,2018,62:50-60. [25] WU Y,ZHOU B P.New insights of epithelial-mesenchymal transition in cancer metastasis[J].Acta Biochimica et Biophysica Sinica (Shanghai),2008,40(7):643-650. [26] YIN P,WANG W,ZHANG Z,et al.Wnt signaling in human and mouse breast cancer:Focusing on Wnt ligands,receptors and antagonists[J].Cancer Science,2018,109(11):3368-3375. [27] DARAKHSHAN S,GHANBARI A.Tranilast enhances the anti-tumor effects of tamoxifen on human breast cancer cells in vitro[J].Journal of Biomedical Science,2013,20:76. [28] NIENHUIS H H,ARJAANS M,TIMMER-BOSSCHA H,et al.Human stromal cells are required for an anti-breast cancer effect of zoledronic acid[J].Oncotarget,2015,6(27):24436-24447. [29] SOKOL J P,NEIL J R,SCHIEMANN B J,et al.The use of cystatin C to inhibit epithelial-mesenchymal transition and morphological transformation stimulated by transforming growth factor-β[J].Breast Cancer Research,2005,7(5):R844-853. [30] TSAO S M,HSU H Y.Fucose-containing fraction of Ling-Zhi enhances lipid rafts-dependent ubiquitination of TGFβ receptor degradation and attenuates breast cancer tumorigenesis[J].Scientific Reports,2016,6:36563. [31] SUN Y,ZHOU Q M,LU Y Y,et al.Resveratrol inhibits the migration and metastasis of MDA-MB-231 human breast cancer by reversing TGF-β1-induced epithelial-mesenchymal transition[J].Molecules,2019,24(6):1131. [32] YU Y,LUO W,YANG Z J,et al.miR-190 suppresses breast cancer metastasis by regulation of TGF-β-induced epithelial-mesenchymal transition[J].Molecular Cancer,2018,17(1):70. [33] YIN K,YIN W,WANG Y,et al.miR-206 suppresses epithelial mesenchymal transition by targeting TGF-β signaling in estrogen receptor positive breast cancer cells[J].Oncotarget,2016,7(17):24537-24548. [34] NING J,ZHAO Y,YE Y,et al.Opposing roles and potential antagonistic mechanism between TGF-β and BMP pathways:Implications for cancer progression[J].EBioMedicine,2019,41:702-710. [35] ZHU X,HUANG S,ZENG L,et al.HMOX-1 inhibits TGF-β-induced epithelial-mesenchymal transition in the MCF-7 breast cancer cell line[J].International Jouranl of Molecular Medicine,2017,40(2):411-417. [36] HAMDOUN S,EFFERTH T.Ginkgolic acids inhibit migration in breast cancer cells by inhibition of NEMO sumoylation and NF-κB activity[J].Oncotarget,2017,8(21):35103-35115. [37] HAN D,WU G,CHANG C,et al.Disulfiram inhibits TGF-β-induced epithelial-mesenchymal transition and stem-like features in breast cancer via ERK/NF-κB/Snail pathway[J].Oncotarget,2015,6(38):40907-40919. [38] SPERLICH J,KERR R,TEUSCH N.The marine natural product pseudopterosin blocks cytokine release of triple-negative breast cancer and monocytic leukemia cells by inhibiting NF-κB signaling[J].Marine Drugs,2017,15(9):262. [39] 魏业东.大黄素通过Wnt/β-catenin信号通路抑制三阴性乳腺癌转移及EMT效应的体外研究[D].上海:华东理工大学,2018. WEI Y D.Emodin inhibit triple negative breast cancer epithelial-mesenchymal transtition and cell metastasis via Wnt/β-catenin signaling in vitro[D].Shanghai:East China University of Science and Technology,2018.(in Chinese) [40] MA X,YAN W,DAI Z,et al.Baicalein suppresses metastasis of breast cancer cells by inhibiting EMT via downregulation of SATB1 and Wnt/β-catenin pathway[J].Drug Design Development Therapy,2016,10:1419-1441. [41] REN L,CHEN H,SONG J,et al.miR-454-3p-mediated Wnt/β-catenin signaling antagonists suppression promotes breast cancer metastasis[J].Theranostics,2019,9(2):449-465. |